Table 3.
Subgroup analyses for survival rate, relapse, and overall response rate.
| Outcomes | Factors | Subgroup | RR and 95%CI | P | Heterogeneity (%) | P value for heterogeneity | P value between subgroups |
| 1-year survival rate | Percentage male | ≥70.0% | 1.05 (0.92–1.19) | .511 | 32.2 | .194 | .853 |
| <70.0% | 1.04 (0.86–1.25) | .701 | 59.0 | .062 | |||
| Performance status | 0–1 | 0.96 (0.84–1.11) | .584 | 39.3 | .144 | .052 | |
| 0–2 | 1.20 (1.03–1.41) | .023 | 0.0 | .478 | |||
| Weight loss | <5.0% | 1.01 (0.84–1.22) | .902 | 0.0 | .690 | .637 | |
| <10.0% | 1.07 (0.92–1.24) | .397 | 43.0 | .135 | |||
| Stage | III | 1.04 (0.95–1.15) | .415 | 24.4 | .235 | 1.000 | |
| Both | 0.98 (0.55–1.76) | .950 | 82.9 | .016 | |||
| Study quality | High | 1.08 (0.97–1.20) | .161 | 0.0 | .817 | .252 | |
| Low | 1.01 (0.82–1.25) | .905 | 66.3 | .018 | |||
| 2-year survival rate | Percentage male | ≥70.0% | 1.35 (1.03–1.76) | .028 | 38.7 | .163 | .614 |
| <70.0% | 1.18 (0.91–1.53) | .211 | 25.3 | .260 | |||
| Performance status | 0–1 | 1.24 (0.92–1.66) | .156 | 47.5 | .107 | .668 | |
| 0–2 | 1.61 (0.86–3.01) | .136 | 57.8 | .124 | |||
| Weight loss | <5.0% | 1.13 (0.76–1.70) | .549 | – | – | .954 | |
| <10.0% | 1.28 (0.96–1.70) | .095 | 45.0 | .122 | |||
| Stage | III | 1.24 (1.08–1.43) | .002 | 0.0 | .623 | .959 | |
| Both | 1.51 (0.42–5.40) | .522 | 83.9 | .013 | |||
| Study quality | High | 1.29 (1.06–1.57) | .011 | 0.0 | .749 | .671 | |
| Low | 1.27 (0.96–1.69) | .097 | 50.6 | .072 | |||
| 3-year survival rate | Percentage male | ≥70.0% | 1.38 (1.04–1.84) | .027 | 0.0 | .415 | .370 |
| <70.0% | 1.12 (0.77–1.62) | .563 | 0.0 | .513 | |||
| Performance status | 0–1 | 1.07 (0.76–1.50) | .702 | 0.0 | .440 | .334 | |
| 0–2 | 1.61 (1.04–2.47) | .031 | 0.0 | .695 | |||
| Weight loss | <5.0% | 1.00 (0.60–1.67) | .990 | – | – | .338 | |
| <10.0% | 1.25 (0.93–1.68) | .136 | 0.0 | .433 | |||
| Stage | III | 1.33 (1.05–1.68) | .017 | 0.0 | .689 | .166 | |
| Both | 0.68 (0.27–1.70) | .413 | – | – | |||
| Study quality | High | 1.40 (1.07–1.84) | .015 | 0.0 | .746 | .224 | |
| Low | 1.04 (0.66–1.64) | .862 | 12.4 | .319 | |||
| 4-year survival rate | Percentage male | ≥70.0% | 1.53 (1.05–2.22) | .026 | 0.0 | .939 | .780 |
| <70.0% | 1.31 (0.65–2.62) | .450 | – | – | |||
| Performance status | 0–1 | 1.37 (0.87–2.16) | .178 | 0.0 | .868 | .775 | |
| 0–2 | 1.65 (0.92–2.95) | .093 | – | – | |||
| Weight loss | <5.0% | 1.60 (1.09–2.35) | .017 | 0.0 | .494 | .986 | |
| <10.0% | 1.53 (1.01–2.32) | .047 | 0.0 | .722 | |||
| Stage | III | 1.48 (1.06–2.05) | .020 | 0.0 | .965 | .556 | |
| Both | 1.75 (1.10–2.78) | .018 | – | – | |||
| Study quality | High | 1.61 (1.21–2.15) | .001 | 0.0 | .955 | .587 | |
| Low | 1.31 (0.65–2.62) | .450 | – | – | |||
| 5-year survival rate | Percentage male | ≥70.0% | 1.65 (1.05–2.58) | .029 | 0.0 | .394 | .540 |
| <70.0% | 1.35 (0.88–2.09) | .173 | 0.0 | .369 | |||
| Performance status | 0–1 | 1.42 (0.72–2.80) | .317 | 32.8 | .223 | .773 | |
| 0–2 | 1.81 (0.98–3.35) | .059 | – | – | |||
| Weight loss | <5.0% | 1.35 (0.88–2.09) | .173 | 0.0 | .369 | .334 | |
| <10.0% | 1.88 (1.16–3.07) | .011 | 0.0 | .830 | |||
| Stage | III | 1.49 (1.09–2.04) | .012 | 0.0 | .550 | – | |
| Both | – | – | – | – | |||
| Study quality | High | 1.61 (1.14–2.26) | .006 | 0.0 | .595 | .283 | |
| Low | 1.01 (0.46–2.20) | .986 | – | – | |||
| Locoreginal relapse | Percentage male | ≥70.0% | 0.83 (0.65–1.06) | .135 | 27.7 | .246 | .525 |
| <70.0% | 0.77 (0.64–0.92) | .005 | 0.0 | .691 | |||
| Performance status | 0–1 | 0.80 (0.67–0.97) | .020 | 7.6 | .363 | .920 | |
| 0–2 | 0.73 (0.49–1.09) | .125 | 34.2 | .218 | |||
| Weight loss | <5.0% | 0.79 (0.64–0.98) | .029 | 0.0 | .935 | .638 | |
| <10.0% | 0.83 (0.61–1.13) | .237 | 50.9 | .131 | |||
| Stage | III | 0.76 (0.65–0.88) | <.001 | 0.0 | .817 | .079 | |
| Both | 1.06 (0.75–1.50) | .737 | – | – | |||
| Study quality | High | 0.78 (0.64–0.94) | .011 | 0.0 | .632 | .672 | |
| Low | 0.81 (0.65–1.03) | .082 | 27.1 | .249 | |||
| Distant relapse | Percentage male | ≥70.0% | 1.06 (0.89–1.27) | .514 | 0.0 | .936 | .764 |
| <70.0% | 0.94 (0.69–1.28) | .697 | 40.6 | .168 | |||
| Performance status | 0–1 | 0.92 (0.75–1.14) | .450 | 0.0 | .477 | .481 | |
| 0–2 | 1.12 (0.88–1.42) | .363 | 0.0 | .412 | |||
| Weight loss | <5.0% | 0.92 (0.67–1.28) | .628 | 35.5 | .212 | .768 | |
| <10.0% | 1.07 (0.89–1.28) | .490 | 0.0 | .833 | |||
| Stage | III | 1.02 (0.88–1.18) | .792 | 0.0 | .539 | .922 | |
| Both | 1.00 (0.73–1.37) | 1.000 | – | – | |||
| Study quality | High | 1.09 (0.92–1.29) | .310 | 0.0 | .975 | .189 | |
| Low | 0.91 (0.74–1.12) | .384 | 1.8 | .396 | |||
| Locoreginal plus distant relapse | Percentage male | ≥70.0% | 0.67 (0.37–1.24) | .206 | 0.0 | .916 | .409 |
| <70.0% | 0.93 (0.58–1.49) | .769 | 0.0 | .803 | |||
| Performance status | 0–1 | 0.62 (0.30–1.28) | .200 | 0.0 | .910 | .670 | |
| 0–2 | 0.92 (0.48–1.80) | .816 | 0.0 | .581 | |||
| Weight loss | <5.0% | 0.87 (0.52–1.46) | .590 | 0.0 | .864 | .639 | |
| <10.0% | 0.65 (0.33–1.27) | .209 | 0.0 | .743 | |||
| Stage | III | 0.83 (0.57–1.20) | .316 | 0.0 | .936 | – | |
| Both | – | – | – | – | |||
| Study quality | High | 0.79 (0.52–1.20) | .270 | 0.0 | .881 | .646 | |
| Low | 0.98 (0.43–2.22) | .963 | 0.0 | .518 | |||
| Overall response rate | Percentage male | ≥70.0% | 1.08 (0.90–1.30) | .383 | 58.2 | .048 | .924 |
| <70.0% | 1.19 (1.00–1.40) | .047 | 55.7 | .079 | |||
| Performance status | 0–1 | 1.00 (0.89–1.13) | .948 | 0.0 | .461 | .008 | |
| 0–2 | 1.42 (1.05–1.91) | .022 | 66.1 | .086 | |||
| Weight loss | <5.0% | 1.12 (1.00–1.25) | .059 | 0.0 | .588 | .737 | |
| <10.0% | 1.02 (0.77–1.35) | .904 | 79.2 | .008 | |||
| Stage | III | 1.17 (1.07–1.27) | .001 | 22.2 | .239 | .021 | |
| Both | 0.87 (0.68–1.11) | 0.261 | – | – | |||
| Study quality | High | 1.19 (1.09–1.29) | <.001 | 0.0 | .540 | .184 | |
| Low | 1.10 (0.90–1.34) | .354 | 63.8 | .026 |